After months of negotiations and anticipation, the Trump administration finally rolled out the first of its deals with drugmakers under its “most favored nation” policy. We’ve been tracking talks between drugmakers and the White House, and Tuesday’s announcement is a big deal — but with some big caveats.
Today on Post-Hoc Live, we spoke to Brookings Institution senior fellow and healthcare expert Marta Wosińska, biotech political consultant and head of Cronus Consulting Nick Shipley, and Endpoints News pharma reporter Max Bayer, who was at the White House on Tuesday for the announcement.
You can watch the YouTube stream, or listen on Spotify and Apple Podcasts.
We got into the politics of the deal, what it means in the direct-to-consumer and Medicaid markets, who is going to buy drugs on TrumpRx.gov, the implications for other drugmakers, and what comes next. Thanks for watching!
— Drew Armstrong, Executive Editor
↧